SCHEMBL6493472

SCHEMBL6493472

Cc1cc2cc(NC(=O)C3CCC(=O)C3)ccc2n1C(=O)c1c(F)cccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.44
PARP15 Q460N3 1/20 0.44
PARP10 Q53GL7 1/20 0.44
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MGLL Q99685 1/20 0.38
GAA P10253 3/20 0.38
MAPT P10636 2/20 0.38
MALT1 Q9UDY8 3/20 0.38
MAOB P27338 1/20 0.37
POLB P06746 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PDE2A O00408 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
RORC P51449 1/20 0.36
EPHX2 P34913 1/20 0.35
PTGES O14684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490688 0.90 MGLL (0.44) NPC1RAB9ASMN1; SMN2MGLLGAA
SCHEMBL6480758 0.89 PARP1 (0.42) PARP1PARP15PARP10SMN1; SMN2MAPT
SCHEMBL6492402 0.88 NPSR1 (0.46) NPC1RAB9ASMN1; SMN2MGLLMALT1
SCHEMBL6489974 0.88 JAK2 (0.43) NPC1RAB9ASMN1; SMN2MGLLGAA
SCHEMBL6492666 0.87 NPSR1 (0.45) NPC1RAB9ASMN1; SMN2MGLLMALT1
SCHEMBL6492249 0.87 PARP1 (0.48) PARP1PARP15PARP10NPC1RAB9A
SCHEMBL6489116 0.84 HSD17B10 (0.44) SMN1; SMN2MGLLGAAMAPTMAOB
SCHEMBL6494500 0.84 PARP1 (0.45) PARP1PARP15PARP10MALT1POLB
SCHEMBL6487994 0.83 MEN1 (0.46) SMN1; SMN2MGLLMAPTMALT1
SCHEMBL6480722 0.82 NPSR1 (0.49) SMN1; SMN2MAOBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors IDO1, IDO2, HAVCR2 PARP1 3678/4885PARP15 2460/4885PARP10 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.